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See Article, pages 74–80Different terms have been used in the literature for acute liver
failure (ALF), i.e., fulminant hepatitis or necrosis, fulminant and
subfulminant hepatic failure, and various deﬁnitions have been
proposed [1–3]. In a systematic review of 41 deﬁnitions of ALF,
Wlodzimirow and co-workers identiﬁed 4 components that
underlined the deﬁnition of ALF and accounted for the differ-
ences: presence and/or grading of hepatic encephalopathy (HE),
the interval between onset of disease and occurrence of HE,
presence of coagulopathy, and pre-existing liver disease [4].
More than 90% of the patients who developed an acute hepa-
titis episode would recover spontaneously. Recovery rate is even
higher mainly if the triggering event is related to certain etiolo-
gies, i.e., hepatitis A virus, transient hypoxia, paracetamol intox-
ication, and mushroom poisoning [5,6]. The acute hepatitis
episode is considered to be severe and named also ‘‘acute liver
injury’’ (ALI) when the liver synthetic function, expressed by a
coagulation marker, is reduced, namely prothrombin time ratio
rate 650% or an international normalized ratio (INR) P1.5 and
the disease occurs within less than a 26-week period. The acute
severe episode is considered to be fulminant and named ‘‘ALF’’
when early neurological manifestations of the disease, mainly
hepatic encephalopathy, appear. ALF is a distinct syndrome that
should be differentiated from acute-on-chronic liver failure that
develops in patients with decompensated cirrhosis [7].
More recently, Polson and Lee with the group of AASLD
deﬁned ALF as evidence of coagulation abnormality, usually an
INRP1.5, and any degree of mental alteration (encephalopathy),
in a patient without pre-existing cirrhosis and with an illness of
626-week duration. To note, patients with Wilson disease, verti-
cally-acquired HBV, or autoimmune hepatitis may be included in
spite of the possibility of cirrhosis if their disease has only been
recognized for 626 weeks [8]. The group also highlighted that
the distinctions according to the delay between onset of jaundice
and HE, such as hyperacute or fulminant, acute or subfulminant
and subacute, do not have prognostic signiﬁcance distinct from
the cause of illness. Despite various deﬁnitions in the literature,
the occurrence of HE during the course of the disease appears
to be the landmark of a critical progression. HE, the main compli-
cation in patients with ALF, is almost always complicated by
cerebral oedema, leading to increased intracranial pressure andJournal of Hepatology 20
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encephalopathy is essential.
The progression from a severe acute hepatitis episode or ALI
to ALF remains unpredictable and this raised an essential ques-
tion as to when to transfer these patients to a transplant centre
and/or to a liver ICU. It is estimated that approximately 30% of
these patients would develop an ALF. Patients with ALF related
to viral etiology and those with undetermined cause of liver fail-
ure are more likely to develop HE and have a worse outcome.
Takikawa et al. reported in their study that age >50, prolonged
prothrombin time, elevation of total bilirubin, and non-A-E hep-
atitis were risk factors for encephalopathy development in
patients with severe acute hepatitis [9]; these factors were close
to the King’s College criteria for liver transplantation for patients
with non-paracetamol induced ALF. Bernuau et al. proposed crite-
ria for patients with severe acute hepatitis and high risk of devel-
oping HE, according to the degree of severity of prothrombin time
ratio, for immediate transfer to a liver unit with liver transplant
facilities [10]. In the manuscript by Bernal and co-workers in this
issue of the Journal, the authors did consider referral to a liver ICU
in patients with ALI and ALF, progressive coagulopathy with
INR >2 or PT >30 s or development of extrahepatic organ failure.
Gene polymorphism might have an important role in determin-
ing patients at risk of developing ALF as it has been shown
recently for acetaminophen-induced liver failure, and this would
need to be conﬁrmed with other series and determined for vari-
ous etiologies [11].
In their study, Bernal and co-workers reported their huge
experience on 3300 acute liver patients treated in their liver
ICU since 1973, among them 2095 patients with ALF. They mainly
focused on the changes that occurred during the last thirty years
in the epidemiology, disease severity, therapeutics, and outcomes
of patients with ALF. This is one of the biggest series ever
reported in a single centre. They did observe in the recent period
a signiﬁcant decrease in paracetamol induced-hepatitis. This is in
contrast to a constant increase observed in the United States
(46%) and in France (20%) [5,6]. The difference among countries
is probably related to the fact that in the early King’s College
experience, suicide attempt of paracetamol etiology was extre-
mely high (60.9%) and, moreover, according to the authors, to
the introduction of paracetamol sales restriction in the United
Kingdom in 1988. Of note, the proportion of patients who
underwent liver transplantation for paracetamol-induced ALF,13 vol. 59 j 6–8 Open access under CC BY-NC-ND license.
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did not change overtime and varied between 36% and 39% of the
patients in the King’s college experience. Current data from the
European Liver Transplant Registry (ELTR) in 4903 adult patients
(>16 years) transplanted for ALF, paracetamol overdose repre-
sented merely 12% of the indications [12]. Transplantation for
paracetamol-induced ALF increased seven-fold from 2% (1973–
1978) to 14.1% (2004–2008) [12].
A major decrease in HBV and HAV viral related etiology was
observed in all reported series in Europe and in the USA. This is
probably related to the vaccination campaign and the awareness
of viral transmission among adults since the 1990s. In the expe-
rience of the King’s college reported in this issue of the Journal,
viral hepatitis fell signiﬁcantly from 55.9% (1973–1978) to
16.6% (2004–2008) of all non-paracetamol cases. Viral etiology
represented 21% of the indications of liver transplantation for
ALF. Liver transplantation for ALF due to HAV and HBV decreased
signiﬁcantly in the last 5 years (from 1% to 0.5% and from 17.9% to
13.2%, respectively).
Treatment in the intensive care unit of patients with ALF has
been limited. Before the advent of liver transplantation, the over-
all mortality rate in patients with acute liver failure ranged from
80% to 85%. Liver transplantation has been a major improvement
and became the standard management of these patients since the
late 1980s [13,14]. Bernal and co-workers reported, in the 387
patients who underwent a liver transplantation, a survival
increase from 56% for the period 1984–1988 to 86% for the period
2004–2008. Survival after liver transplantation was recently eval-
uated in 4903 patients with ALF reported in the ELTR. One, 5- and
10-year patient and graft survival rates were 74%, 68%, 63%, and
63%, 57%, 50%, respectively. Survival became better during the
period 2004–2009 compared to the previous quinquennia
(p <0.001), despite that donors >60 years increased from 1.8% to
21% [12]. This has also been recently observed in the national
French trial with a major improvement in the results reaching a
one-year patient survival of 89% among those patients who
underwent liver transplantation [15]. The reasons are probably
related to several factors: (1) early transfer of patients with acute
severe hepatitis to transplant centre before the occurrence of
hepatic encephalopathy, (2) a dramatic decrease of patients with
ALF admitted with hepatic encephalopathy grade IV in our study,
(3) a signiﬁcant fall in proportion of patients admitted with signs
of intracranial hypertension from 76% in 1984–1988 to 19.8% in
2004–2008 in the study by Bernal et al. in this issue of the Journal,
(4) early introduction of medical management mainly for para-
cetamol and viral etiologies, (5) improvement in the overall man-
agement of patients admitted to the liver ICU such as monitoring,
prevention, and treatment of early signs of intracranial hyperten-
sion (ICH), hypothermia control, microbiological surveillance and
prophylaxis, renal replacement therapy modalities, (6) technical
improvement in the transplant surgery and the perioperative
care. Despite a great improvement in survival rates after liver
transplantation, some patients still die before, during, or after
transplantation, mainly as a result of irreversible brain damage.
In addition to the scarcity of organ donors, and due to the emer-
gency conditions, poor quality grafts, which have a high risk of
graft failure, are frequently used. These factors have been a limi-
tation to the improvement in the results of liver transplantation
for acute liver failure.
Medical management of patients in the ICU has mildly
improved in the late 1990s and this included speciﬁc early inter-
ventions to prevent and treat ICH, hemodynamic and sepsis
management, and renal replacement modalities. Despite someJournal of Hepatology 2recent improvements, transplant-free survival rates of these
patients, who were often in a good condition before the onset
of ALI, remain low [10,16]. In the manuscript of Bernal et al., they
observed an improvement in hospital survival among patients
who were not transplanted only in paracetamol etiology, non-
paracetamol drug, and viral etiologies. However, in their study,
the development of ICH was strongly associated with increased
mortality (73.6% among 648 patients with ICH) and 55% of their
most recent patients (2003–2008) who developed ICH died.
A major therapeutical improvement in the management of
patients with ALF is still needed. In recent years, there has been
a considerable interest in the use of newer forms of liver support
that may provide a bridge until a spontaneous recovery of the
liver or until an appropriate donor is available or better in order
to improve transplant-free survival. A recent meta-analysis on
extracorporeal liver support therapies (ELS) included eight RCTs,
three addressing acute liver failure (198 participants). They
showed that ELS therapy signiﬁcantly improved survival in acute
liver failure (risk ratio 0.70; p = 0.05). The number of patients
needed to treat (NNT), to prevent one death from acute liver fail-
ure, was eight [17]. Therefore, there might be a potential place for
the use of ELS in this setting. Over the last decade, the Molecular
Adsorbent Recirculating System (MARS) that uses albumin dial-
ysis has been widely used. The MARS system has demonstrated
interesting results in controlled and uncontrolled trials in
improving short-term survival. However, in a recent randomized
controlled trial performed in 102 patients with ALF, MARS did not
show superiority compared to a control group [15]. In this study,
75% of the patients were transplanted within 24 h. This highlights
the difﬁculties to run such trials and raises a major debate on
how to evaluate future ELS devices in the advent of liver
transplantation.
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